Perinatal transmission of human papillomavirus type 16 (HPV-16) and persistence of virus DNA in infants until 6 months of age has been described. To confirm the origin of infant infections as maternal, we determined the nucleotide sequence of the upstream regulatory region (URR; bp 7540 to 157) of HPV-16 in samples from 13 HPV-16 DNA-positive mothers and their infants at 6 weeks and 2 years of age. Identical HPV-16 variant URR sequences were found in two mother/infant samples and similar variants were found in three sets.
Four mothers with samples which contained prototypic HPV-16 sequences delivered infants who also had the prototypic sequence. Four mothers with variant URRs delivered infants who harboured either prototypic or different URR variants. Thus, concordant variants or prototypic sequences were detected in nine of 13 mother/infant samples, indicating that up to 69.2% of HPV-16-positive infants acquire virus from their mothers.
Human papillomavirus type 16 (HPV-16) is implicated in the aetiology of cervical carcinoma and is considered to be high cancer risk (Lorincz et al., 1992) . Site specificity of this genital HPV and the fact that cervical carcinoma displays the epidemiology of a sexually-transmitted disease (Munoz & Bosch, 1989) led to the presumption that this virus was transmitted by sexual contact.
Many agents, including other members of the Papovaviridae such as polyomavirus JC (Kunitake et al., 1995) and low-risk genital HPVs, may be transmitted from parent to child. Moreover, HPV-16 infections amongst children have been documented. HPV-16 DNA has been found on foreskins (Roman & Fife, 1986) , in nasopharyngeal aspirates (Sedlaceck et al., 1989; Cason et al., 1995) , in buccal cavities (Jenison et al., 1990; Cason et al., 1995) and occasionally in condylomata acuminata and laryngeal carcinomas of children (Rock et al., 1986; Simon et al., 1994) . Antibodies to HPV-16 have also been detected in up to 40 % of childrens' sera (JochmusKudielka et al., 1989; Jenison et al., 1990) . Further evidence of infant infection is provided by the finding that HPV DNA occurs in 75 % to 83 % of samples from infants delivered by HPV-16-or HPV-18-infected mothers (Fredericks et al., 1993; Cason et al., 1995) and * Author for correspondence. Fax +44 171 928 0730. that in such cases transmission is dependent upon maternal viral load (Kaye et al., 1994) . Although infection in newborn infants is assumed to occur during delivery, HPV-16 DNA has been detected in infants whose mothers were HPV-16 DNA-negative (Cason et al., 1995) , suggesting other sources of infection exist.
To determine the incidence of mother-to-infant HPV-16 transmission, we sequenced a 521 bp segment of the upstream regulatory region (URR) of HPV-16 DNA isolated from 13 maternal samples and from samples taken from their (13) infants (eight female) at 6 weeks and 2 years of age. The URR was studied since it is particularly prone to variation (Xi et al., 1993 (Xi et al., , 1995 Ho et al., 1993; May et al., 1994) .
Mothers (11 Caucasian and two Negroid) had a mean age of 32 years (range 2442) at delivery; two had a history of anogenital warts and four of previous abnormal cervical smears. These mothers were selected from 61 pregnant women, recruited from ante-natal clinics at St Thomas' Hospital (London, UK) for donation of specimens from themselves and their infants; data regarding transmission and persistence of HPV-16 DNA in these infants have been published elsewhere (Cason et al., 1995) . Informed consent was obtained and approval granted by the Research Ethics Committee of St Thomas' Hospital.
Maternal cell scrapes were collected from the cervix 0001-3763 © 1996 SGM (Cavuslu et al., 1996) and by Southern blotting of PCR products using a 32p_ labelled E5 probe (bp 3908 3935). All samples were PCR-positive for fl-globin, indicating sufficient DNA was present for analyses (Saiki et al., 1986) .
Mothers Infants
Case and posterior vaginal fornix using sterile wooden spatulas at between 20 to 38 weeks of gestation by a gynaecologist. Swabs were also taken from the buccal mucosa and penile shaft of male infants and buccal mucosa, mons pubis and labia of female infants; only buccal swabs were taken at 2 years of age. Infants were considered HPV-16-positive if E5 DNA was detected at buccal and/or at genital sites by both PCR and Southern blot; buccal samples from children were used for sequencing (Table 1 ). All samples were considered to contain sufficient DNA for analysis since all produced amplicons of the correct size in PCR for fl-globin (Saiki et al., 1986) .
HPV-16 DNA from clinical samples was amplified for sequencing in nested PCRs using Taq DNA polymerase and HPV-16 external and internal primers. The external primers have been described previously (Xi et al., 1993) : primer C, upstream, bp 7445-7468 (5' GCTTCAACC-GAATTCGGTTGCATG 3'); primer D, downstream, bp 192-222 (3' CACACATGACGTTCGTTGTCAAT-GACGCTGC 5'). Internal primers were: upstream, bp 7503-7520 (5' CTATGTCAGCAACTATGG 3'); downstream, bp 158-176 (3' GACGTTTGTTGATAT-GTAC-biotin 5') ( Fig. 1 ). Development and usage of nested PCRs to produce material for sequencing was necessary for two reasons. Firstly, samples had been analysed previously in 14 different PCRs and we had limited amounts of target remaining. Secondly, samples from children contained low quantities of HPV-16 DNA, which were not always detected by PCR using HPV consensus primers but were detectable when more sensitive PCRs based on primers in the E5, E6 or E7 ORFs were used (Cavuslu et al., 1996) . Indeed, even when nested PCRs were used to amplify target DNA for sequencing, sufficient quantities of DNA for use with the AutoRead Sequencing Kit (Pharmacia) were only obtained by pooling the products of three nested PCRs for each sample.
DNA was extracted with phenol-chloroform and sequenced. Appropriate precautions were taken to prevent contamination of PCR reactions, and negative controls (water and HPV DNA-negative A431 cells; one of each per six clinical samples) were included in all PCR runs. Maternal and infant samples were amplified and sequenced on different occasions to prevent any possibility of cross-contamination.
Biotinylated antisense amplicons were isolated using 
streptavidin-coated magnetic beads (Dynal). Sequencing primers [bp 7522-7539 (5' FITC-TTAAACTTGTACG-TTTCC 3') and 7748-7768 (5' FITC-TAAGGTTTAAACTTCTAAGGC 3')] were used to sequence the HPV-16 isolates between bp 7540 and 157 in reactions performed with a commercial kit utilizing T7 DNA polymerase (AutoRead; Pharmacia). Sequencing products were analysed on an automated DNA sequencer (ALF; Pharmacia). Positive controls included CaSki cell DNA (ATCC) and pAt-HPV-16 DNA (provided by E.-M. de Villiers, DKFZ, Heidelberg, Germany).
All samples from mothers and infants, and pAt-HPV-16, contained a deletion at nucleotide 7863 (A) as noted by others (May et al., 1994) when aligned to the sequence described by Seedorf et al. (1985) ; CaSki cell DNA also had the change A to T at this position (data not shown). Other common occurrences were deletions of nucleotide 7624 (G) and, more frequently, of nucleotide 7625 (C) ( Table 2 ). The same deletion occurred in pAt-HPV-16, but both nucleotides 7624 and 7625 were unchanged in CaSki cell DNA. Since variants containing these deletions were common they were considered poor markers (and may even represent sequencing artefacts) for investigating the source of HPV-16 infections (Ho et al., 1993) . For the purposes of the present study, prototypic HPV-16 sequence was considered to be that described by Seedorf et al. (1985) with deletions at positions 7625 and 7863.
Overall, amongst 13 mothers, eight (61% ; cases 4, 5, 14, 17, 75, 24, 28 and 48) had variant sequences detected in two independent sequencing reactions ( Table 2 ). This was a somewhat higher incidence of variants than reported for a cohort of 28 pregnant women from Seattle (Wash., USA), amongst whom 11 (39"2 %) harboured variant HPV-16 sequences (Xi et at., 1995) . The five mothers from whom prototypic HPV-16 sequence was recovered (case numbers 16, 21, 31, 60 and 76) had infants from whom prototypic HPV-16 DNA was also found at 6 weeks (21, 60 and 76) or at 2 years (16, 21, 31 and 76) (data not shown). The 6 week samples from two infants (cases 16 and 31) and the 2 year sample from another (case 60) were negative for HPV-16 DNA in PCR using E5 or URR primers (Table 1) . It is not known whether these results represent false negatives or whether cases 16 and 31 represent reinfections with prototypic HPV-16 between 6 weeks and 2 years of age.
In two mother/infant sets (cases 4 and 75) identical HPV-16 variants were detected in maternal and infant samples; in case 4, the 2 year sample was positive by PCR for HPV-16 URR and E7 DNA. However, we could not obtain a sufficient amount of the former DNA for sequencing. Taq DNA polymerase has no proofreading activity and amplifications using this enzyme can introduce errors at a rate of 1 per 105 bp; in a 521 bp fragment almost half the amplification products will contain a mutation (Xi et al., 1995) . Since we used direct sequencing, the majority of amplified species present will contain the correct nucleotide at any given position and the sequence derived will thus be a true representation of the DNA template. Statistically, it seems a remote possibility that Taq DNA polymerase errors explain the simultaneous occurrence of identical variants in two sets of mother/infant samples (cases 4 and 75). Indeed, the chance of a nucleotide varying at the same position in three separate samples within the sequenced 521 bp segment is 7 x 10 -9 ([1/521] 3) and the probability of an identical nucleotide replacement (of the three alternate nucleotides) occurring in the same position in all three isolates (as in case 75) is about 2.1x 10 10 ([1/521] 3 x [1/313). Thus, we conclude that in these two instances the mother was the source of persistent infant HPV-16 infections.
Cases 17, 24 and 28 contained both unique and common nucleotide changes in matched maternal and infant samples. Number 17 had a change at bp 12, which also occurs in CaSki cell DNA, although other variations seen in CaSki cell DNA were not observed (May et al., 1994) . However, the corresponding 2-year-old infant's sample contained a deletion at bp 7625. In case 24, all three isolates contained substitution of A for T at bp 7813, but changes at bp 7624 and 7625 were different in these samples. All three matched samples from case 28 contained the same substitution at bp 7572, but whilst the maternal and infant's 6 week sample contained a deletion at bp 7624, this position was intact in the infant's 2 year sample.
Common nucleotide changes in matched maternal and infant samples again implies a maternal source of infant infections. The occurrence of unique nucleotide differences is probably explained by the occurrence of several HPV-16 variants in these cases, as has been described by others (Ho et al., 1991; Xi et al., 1993) . Since direct sequencing was used, sequences obtained represent an 'average' sequence dependent upon the relative quantities of any HPV-16 variants present at any particular time; this would explain the occurrence of both sequence similarities and dissimilarities between matched samples.
Three mothers (case numbers 5, 14 and 48) had variant URR sequences but their infants had prototypic or different variants at 6 weeks or 2 years of age. These data may reflect either (i) re-infections in the infant from an unknown source or (ii), again, that all three samples were from subjects with heterogeneous HPV-16 infections with different variants predominating at different sample times.
Whilst some studies have suggested that there may be hot spots within the URR which are particularly prone to mutation (Xi et al., 1995) , only one of the variants we identified (case 17 at bp 12) has been reported by others (May et al., 1994) . The higher level of variation noted in this paper may be explained by the fact that we used direct sequencing of bulk PCR products. This would more readily reveal variants than the use of cloning, which is problematic when one considers the selection of colonies and the fact that Taq DNA polymerase-induced errors will not be negated by deriving an average sequence.
As it is probable that the source of infection in five mother/infant sample sets with prototypic URRs may be maternal, prevalence of maternally-derived persistent HPV-16 infections of infants may be between two out of 13 (15.4 %; cases where identical variants were detected in matched samples) and nine out of 13 (69.2 %; cases where identical and similar variants, and prototypic sequence, were found in matched samples).
We were unable to sequence isolates from infants more than once because of the low levels of HPV-16 DNA in infants samples (see above). Nevertheless, maternal samples were sequenced at least twice and in several cases, also analysed by single-stranded conformationdependent polymorphism (SSCP; Xi et al., 1993) . For example, maternal and infant samples from case 17 exhibited concordant, but aberrant, SSCP migration when compared to pAt-HPV-16 DNA (data not shown) and, by sequencing, were confirmed as variants.
Our results suggest that there are probably two sources of infant HPV-16 infections: firstly, the mother, presumably at delivery; and secondly, an as yet unidentified source(s). These results are of importance when considering (i) the introduction of prophylactic vaccines against HPV-16 and (ii), the aetiological role of HPV-16 in cervical cancer, a disease which undoubtedly depends upon a sexually-transmitted component.
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